Bausch + Lomb gains on new State of Dry Eye survey linking treatment to better quality of life
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B | $3.78B | $3.67B |
| Cost of Revenue | $1.87B | $1.64B | $1.52B | $1.47B | $1.28B | $1.33B | $1.31B |
| Gross Profit | $2.92B | $2.50B | $2.25B | $2.30B | $2.13B | $2.45B | $2.35B |
| Gross Margin | 60.93% | 60.40% | 59.69% | 61.04% | 62.34% | 64.88% | 64.17% |
| Operating Expenses | $2.76B | $2.37B | $2.04B | $1.97B | $1.87B | $2.06B | $1.94B |
| Operating Income | $162.00M | $130.00M | $207.00M | $329.00M | $260.00M | $396.00M | $416.00M |
| Operating Margin | 3.38% | 3.14% | 5.49% | 8.74% | 7.62% | 10.48% | 11.35% |
| Net Income | $-317.00M | $-260.00M | $6.00M | $182.00M | $-18.00M | $298.00M | $710.00M |
| Net Margin | -6.62% | -6.27% | 0.16% | 4.83% | -0.53% | 7.89% | 19.37% |
| EPS (Basic) | $-0.90 | $-0.74 | $0.04 | $0.52 | $-0.05 | $0.85 | $2.03 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |